A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype

被引:0
|
作者
C. Pirkevi
S. Lesage
C. Condroyer
H. Tomiyama
N. Hattori
S. Ertan
A. Brice
A. N. Başak
机构
[1] Boğaziçi University,Molecular Biology and Genetics Department, Neurodegeneration Research Laboratory
[2] INSERM,Department of Neurology
[3] UMR S679,Department of Neurology, Cerrahpaşa Faculty of Medicine
[4] Pierre et Marie Curie-Paris6 University,Pitié
[5] UMR S679,Salpêtrière Medical School
[6] Pitié-Salpêtrière,Department of Genetics and Cytogenetics, AP
[7] Federative Institute for Neuroscience Research,HP
[8] IFR 070,undefined
[9] Pitié-Salpêtrière,undefined
[10] Juntendo University School of Medicine,undefined
[11] University of Istanbul,undefined
[12] Pierre and Marie Curie-Paris6 University,undefined
[13] Pitié-Salpêtrière Hospital,undefined
来源
neurogenetics | 2009年 / 10卷
关键词
Parkinson’s disease; Genetics; LRRK2; Haplotype;
D O I
暂无
中图分类号
学科分类号
摘要
The leucine-rich repeat kinase 2 (LRRK2) G2019S mutation is recognized as the most common cause of familial autosomal dominant and also sporadic forms of Parkinson disease (PD). A common founder has been described for most Europeans and all North Africans and Jews; besides, two distinct G2019S LRRK2 haplotypes were found in a small proportion of European families and in Japanese PD patients. This study revealed a Turkish patient heterozygous for the G2019S mutation sharing the Japanese haplotype. To the best of our knowledge, it is the first time that the G2019S-associated Japanese haplotype has been reported in a different population.
引用
收藏
页码:271 / 273
页数:2
相关论文
共 50 条
  • [41] THE ABSENCE OF THE COMMON LRRK2 G2019S MUTATION IN 120 YOUNG ONSET HUNGARIAN PARKINON'S DISEASE PATIENTS
    Balicza Peter
    Bereznai Benjamin
    Takats Annamaria
    Klivenyi Peter
    Dibo Gyoergy
    Hidasi Eszter
    Balogh Istvan
    Molnar Maria Judit
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2012, 65 (7-8): : 239 - 242
  • [42] Fluctuation Imaging of LRRK2 Reveals that the G2019S Mutation Alters Spatial and Membrane Dynamics
    Sanstrum, Bethany J.
    Goo, Brandee M. S. S.
    Holden, Diana Z. Y.
    Delgado, Donovan D.
    Nguyen, Thien P. N.
    Lee, Kiana D.
    James, Nicholas G.
    MOLECULES, 2020, 25 (11):
  • [43] Nonmotor Symptoms in Healthy Ashkenazi Jewish Carriers of the G2019S Mutation in the LRRK2 Gene
    Mirelman, Anat
    Alcalay, Roy N.
    Pullman, Rachel Saunders
    Yasinovsky, Kira
    Thaler, Avner
    Gurevich, Tanya
    Melia-Santana, Helen
    Raymond, Deborah
    Gana-Weisz, Mali
    Bar-Shira, Anat
    Ozelius, Laurie
    Clark, Lorraine
    Orr-Urtreger, Avi
    Bressman, Susan
    Marder, Karen
    Giladi, Nir
    MOVEMENT DISORDERS, 2015, 30 (07) : 981 - 986
  • [44] LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase
    Choi, Insup
    Kim, Beomsue
    Byun, Ji-Won
    Baik, Sung Hoon
    Huh, Hyun
    Kim, Jong-Hyeon
    Mook-Jung, Inhee
    Song, Woo Keun
    Shin, Joo-Ho
    Seo, Hyemyung
    Suh, Young Ho
    Jou, Ilo
    Park, Sang Myun
    Kang, Ho Chul
    Joe, Eun-Hye
    NATURE COMMUNICATIONS, 2015, 6
  • [45] LRRK2 G2019S Mutation Inhibits Degradation of -Synuclein in an In Vitro Model of Parkinson's Disease
    Hu, Dan
    Niu, Jian-yi
    Xiong, Jing
    Nie, Shu-ke
    Zeng, Fei
    Zhang, Zhao-hui
    CURRENT MEDICAL SCIENCE, 2018, 38 (06) : 1012 - 1017
  • [46] A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease
    Omer, Nurit
    Giladi, Nir
    Gurevich, Tanya
    Bar-Shira, Anat
    Gana-Weisz, Mali
    Goldstein, Orly
    Kestenbaum, Meir
    Cedarbaum, Jesse M.
    Orr-Urtreger, Avi
    Mirelman, Anat
    Thaler, Avner
    MOVEMENT DISORDERS, 2020, 35 (07) : 1249 - 1253
  • [47] Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD
    Markos Poulopoulos
    Etty Cortes
    Jean-Paul G. Vonsattel
    Stanley Fahn
    Cheryl Waters
    Lucien J. Cote
    Carol Moskowitz
    Lawrence S. Honig
    Lorraine N. Clark
    Karen S. Marder
    Roy N. Alcalay
    Journal of Molecular Neuroscience, 2012, 47 : 139 - 143
  • [48] The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins
    Moehle, Mark S.
    Daher, Joao Paulo Lima
    Hull, Travis D.
    Boddu, Ravindra
    Abdelmotilib, Hisham A.
    Mobley, James
    Kannarkat, George T.
    Tansey, Malu G.
    West, Andrew B.
    HUMAN MOLECULAR GENETICS, 2015, 24 (15) : 4250 - 4267
  • [49] Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD
    Poulopoulos, Markos
    Cortes, Etty
    Vonsattel, Jean-Paul G.
    Fahn, Stanley
    Waters, Cheryl
    Cote, Lucien J.
    Moskowitz, Carol
    Honig, Lawrence S.
    Clark, Lorraine N.
    Marder, Karen S.
    Alcalay, Roy N.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2012, 47 (01) : 139 - 143
  • [50] Axonal Lysosomal Assays for Characterizing the Effects of LRRK2 G2019S
    Bhatia, Priyanka
    Bickle, Marc
    Agrawal, Amay A.
    Truss, Buster
    Nikolaidi, Aikaterina
    Brockmann, Kathrin
    Reinhardt, Lydia
    Vogel, Stefanie
    Szegoe, Eva M.
    Pal, Arun
    Hermann, Andreas
    Mikicic, Ivan
    Yun, Maximina
    Falkenburger, Bjoern
    Sterneckert, Jared
    BIOLOGY-BASEL, 2024, 13 (01):